Long-term follow-up of treatment-naïve HBeAg-negative patients with chronic hepatitis B.

Abstract

BACKGROUND/AIMS:

We aimed to explore long-term results of oral antiviral agents in treatment-naïve "HBeAg negative chronic hepatitis B (CHB)" and determine the factors affecting the complete virological response.

METHOD:

Patients with HBeAg-negative CHB who used oral antiviral agents for at least 3 years were evaluated retrospectively.

RESULTS:

A total of 173 patients were recorded. The mean duration of treatment was 62.2 ± 28.9 months. Complete virological responses (CVR) were 82.8% (n = 53/64) in tenofovir disoproxil fumarate (TDF), 84.4% (n = 49/58) in lamivudine (LAM), 83.9% (n = 26/31) in entecavir (ETV), 95% in telbivudine (LdT) (n = 19/20) (p = 0.290). Multivariate analysis revealed age ≤ 40 (p = 0.012, 95%CI = 1.38-13.76, OR = 4.36) and baseline HBV DNA value (p = 0.003, 95%CI = 1.23-2.63, OR = 1.78) as independent factors for CVR. Virological breakthrough was detected in 29 (50%) patients on LAM therapy, two (6.4%) patients on ETV therapy, and two (10%) patients on LdT therapy. Treatment was switched to another antiviral agent due to osteoporosis in four patients in the TDF group, muscle pain in nine patients in the LDT group, and headache in one patient in the ETV group. Hepatocelluler cancer was detected in five patients. HBsAg seroclearance developed in two patients. Anti-HBs seroconversion was not detected.

CONCLUSION:

CVR was achieved at similar rates with all four antiviral agents, while younger age (≤ 40) and low baseline viral load were the main factors for virological response. However, drug resistance and virological breakthrough in the LAM group and side effects in the LdT group were detected during the long-term follow-up. Moreover, HBsAg seroclearance was achieved at very low rates with oral antiviral agents.

• Authors: Yusuf Emre Ozdemir, Meryem Sahin Ozdemir, Osman Faruk Bayramlar, Serkan Surme, Sibel Yildiz Kaya, Ridvan Karaali, Ilker Inanc Balkan, Bilgul Mete, Nese Saltoglu, Fehmi Tabak
• Journal: Irish journal of medical science (Ir J Med Sci) Vol. 192 Issue 2 Pg. 633-639 (Apr 2023) ISSN: 1863-4362 [Electronic] Ireland
• PMID: 35715665 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.

Chemical References

• Hepatitis B e Antigens
• Hepatitis B Surface Antigens
• Tenofovir
• Antiviral Agents
• DNA, Viral

Topics

• Humans
• Hepatitis B, Chronic (drug therapy)
• Hepatitis B e Antigens (pharmacology, therapeutic use)
• Hepatitis B Surface Antigens (pharmacology, therapeutic use)
• Retrospective Studies
• Follow-Up Studies
• Treatment Outcome
• Tenofovir (therapeutic use, pharmacology)
• Antiviral Agents (therapeutic use, adverse effects)
• Hepatitis B virus (genetics)
• DNA, Viral (pharmacology, therapeutic use)
• Viral Load